---
title: "Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289087845.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-06-08T11:00:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289087845.md)
  - [en](https://longbridge.com/en/news/289087845.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289087845.md)
---

# Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [<![CDATA[Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg ]]>](https://longbridge.com/en/news/289066296.md)
- [Roche Develops Ebola PCR Test In Six Days Amid Bundibugyo Outbreak](https://longbridge.com/en/news/288802796.md)
- [Roche’s Giredestrant Review Puts Early Breast Cancer Franchise In Focus](https://longbridge.com/en/news/288892413.md)
- [Parabilis eyes $475m IPO to push lead asset into Phase III](https://longbridge.com/en/news/288850252.md)
- [Incyte bolsters haematology portfolio in $2bn Vega buyout](https://longbridge.com/en/news/289087846.md)